Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Syndax Pharmaceuticals (SNDX) PT Raised to $51 at Citi, Opens 90d Catalyst Watch
August 5, 2025 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $51.00 (from $46.00) while maintaining a Buy rating.
Opens 90-Day Upside Catalyst Watch ahead of October 25 PDUFA for Revuforjs sNDA in R/R mNPM1 AML.... More


